Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary NanoString Secures $20M in Series D Financing
NanoString Secures $20M in Series D Financing   New Investors include GE healthymagination Fund, BioMed Ventures and Henri Termeer SEATTLE | November 7, 2011   -  NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular
View HTML
Toggle Summary NanoString Announces Launch of Second Generation nCounter Analysis System
NanoString Announces Launch of Second Generation nCounter Analysis System   New Features Support Larger Translational Research Studies and Development of nCounter-based Diagnostics SEATTLE, Wash. and MONTREAL, Canada | October 12, 2011   -  NanoString Technologies, Inc., a privately held provider
View HTML
Toggle Summary NanoString Introduces Solution for Simultaneously Measuring miRNA and mRNA Expression Levels
NanoString Introduces Solution for Simultaneously Measuring miRNA and mRNA Expression Levels   Kit Enables Profiling of Up To 30 miRNAs and 200 mRNAs in a Single Tube without Amplification SEATTLE, Wash | September 21, 2011   -  NanoString Technologies, Inc., a privately held provider of life
View HTML
Toggle Summary NanoString Introduces Rat miRNA Expression Assays
NanoString Introduces Rat miRNA Expression Assays   Kit Enables Profiling of More than 400 Rat miRNAs in a Single Tube without Amplification SEATTLE, Wash | August 5, 2011   -  NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of
View HTML
Toggle Summary NanoString Embarks on First in Series of Clinical Studies for Breast Cancer Intrinsic Subtyping Assay
NanoString Embarks on First in Series of Clinical Studies for Breast Cancer Intrinsic Subtyping Assay   Study to Evaluate Disease Prognosis Using NanoString? PAM50-based Assay on the TransATAC Sample Set SEATTLE, Wash | August 3, 2011   -  NanoString Technologies, Inc., a privately held provider of
View HTML
Toggle Summary NanoString Offers New Tool for Analyzing 25 Leukemia Fusion Genes in a Single Reaction
NanoString Offers New Tool for Analyzing 25 Leukemia Fusion Genes in a Single Reaction   Multiplexed Assay Kit Provides Simple, Cost-effective Solution to Characterize Samples for Researchers SEATTLE, Wash | July 28, 2011   -  NanoString Technologies, Inc., a privately held provider of life science
View HTML
Toggle Summary Data Supporting Utility of the PAM50 Assay for Breast Cancer Gene Expression Profiling to be Presented at ASCO
Data Supporting Utility of the PAM50 Assay for Breast Cancer Gene Expression Profiling to be Presented at ASCO   NanoString Technologies Developing Distributed Assay Platform for Potential Use in Clinical Diagnostics SEATTLE, Wash., and CHICAGO, Ill | June 3, 2011   -  NanoString Technologies,
View HTML
Toggle Summary NanoString Technologies Introduces Multiplexed Assay Kit for Human Molecular Karyotyping
NanoString Technologies Introduces Multiplexed Assay Kit for Human Molecular Karyotyping   Panel Provides Cost Effective Way to Monitor Cell Line Quality, Perform Cytogenetics Research SEATTLE, Wash | February 22, 2011   -  NanoString Technologies, Inc., a privately held life sciences company
View HTML
Toggle Summary NanoString Technologies Names J. Wayne Cowens, M.D. Chief Medical Officer
NanoString Technologies Names J. Wayne Cowens, M.D. Chief Medical Officer   Veteran industry clinical oncologist to help build company's diagnostics pipeline SEATTLE, Wash | February 1, 2011   -  NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution
View HTML
Toggle Summary NanoString Technologies Introduces Multiplexed Assay Kit for Mouse microRNA Analysis
NanoString Technologies Introduces Multiplexed Assay Kit for Mouse microRNA Analysis   SEATTLE, Wash | January 25, 2011   -  NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological
View HTML